Mandate

VINGE ADVISES BAIN CAPITAL AND BRAVIDA

June 20, 2013

Vinge and Kirkland & Ellis are advising Bain Capital and Bravida in connection with the refinancing of Bravida, which includes the issue of senior secured floating rate notes in the amount of SEK 1.3 billion and EUR 225 million.

Vinge’s team consists of partners Stefan de Hevesy, Christina Kokko and Peter Bäärnhielm together with associates Robin Dangoor, Paul Dali, Charlotta Järnstedt, Andreas Malmberg, Dain Nevonen and Marie Brommesson.

Related

Vinge advises Intrum on its EUR 4.48 billion recapitalisation transaction

Intrum AB and its subsidiaries have completed a comprehensive and strategic recapitalisation transaction aimed at strengthening the company's balance sheet and securing its long-term financial stability. The transaction involves a restructuring of Intrum's existing debt portfolio of approximately EUR 4.48 billion and includes, among other things, an extension of loan maturities, write-downs of existing debt instruments, the injection of new capital from certain of the company's noteholders, and a share issue to existing noteholders. The recapitalisation transaction was implemented through a pre-packaged Chapter 11 process in the United States and a Swedish company reorganisation.
August 25, 2025

Vinge advises Neptuniplan Maritime in financing of ANCS acquisition

Vinge has advised Neptuniplan Maritime Holding AB in connection with entering into a more than EUR 133 000 000 facilities agreement with Citibank, Danske Bank and Nordea for the purpose of, among other things, financing its acquisition of Wärtsilä’s Automation, Navigation and Control Systems (ANCS) business. Operations will be continuing under NACOS Marine, who provides, among other things, advanced solutions in vessel navigation, automation, and control systems, as well as adaptive autopilots and Guidance Marine, a leader in position reference sensor technology for dynamic positioning and maritime safety.
August 25, 2025

Vinge has advised HealthCap on the establishment of HealthCap IX

HealthCap IX has held its final closing, raising total commitments in excess of the target from a diverse investor base comprising established institutions, pension funds, and renowned investors within the life sciences sector. The strong support reflects continued confidence in HealthCap’s strategy and proven track record.
August 22, 2025